NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Doc logic, I understand your point about “post hoc”, but my main point, and “the big lie” is, that NWBio made the endpoint change after the clinical trial data was “unblinded”.

And again, that the trial was still blinded does not mean the analysis was not post-hoc.

We have seen multiple times that BPs have announced results from trials and also said the trial was continuing BLINDED so as to get secondary or co-primary endpoints. There is nothing wrong with this. They are not lying. So one can know information from the trial while still blinded.

NWBO knew the results of the IA that showed the primary endpoint failed. And thus, changing from that was clearly post hoc.

There is a reason this is not getting approved w/o a proper trial.